Back to search
FDAFDA · Food and drugs·Recall number D-0980-2017

Argatroban Injection, 250 mg/2.5 mL (100 mg/mL), 5 mL Single-use vial, Rx Only, Sterile, Manufactured by: Gland Pharma Limited, Hyderabad, India, Manufactured for: Hospira, Inc, Lake Forest, IL 60045 --- NDC 0409-1140-01

Published July 26, 2017 · Recall initiated: July 6, 2017

Summary

FDA records drug Class III recall D-0980-2017, published July 26, 2017 and initiated July 6, 2017. Recalling firm: Hospira Inc., A Pfizer Company; Status: Terminated; Reported quantity: 701 vials; Lot: Lot: DP601, exp 10/2018. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications; out of specification result for denitroquinoline-related impurity during three month time point

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Hospira Inc., A Pfizer Company
Distributor
Nationwide
Lot
Lot: DP601, exp 10/2018
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Argatroban Injection, 250 mg/2.5 mL (100 mg/mL), 5 mL Single-use vial, Rx Only, Sterile, Manufactured by: Gland Pharma Limited, Hyderabad, India, Manufactured for: Hospira, Inc, Lake Forest, IL 60045 --- NDC 0409-1140-01 recalled?

Yes. FDA published recall D-0980-2017 on July 26, 2017. Reported hazard: Failed Impurities/Degradation Specifications; out of specification result for denitroquinoline-related impurity during three month time point

What should I do if I have this product?

Voluntary: Firm initiated · Letter